MLN9708
98%
- Product Code: 206056
CAS:
1201902-80-8
| Molecular Weight: | 517.12 g./mol | Molecular Formula: | C₂₀H₂₃BCl₂N₂O₉ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, dry, sealed |
Product Description:
MLN9708 is a proteasome inhibitor primarily used in the treatment of multiple myeloma, a type of blood cancer. It works by blocking the degradation of proteins involved in cell cycle regulation and apoptosis, leading to the accumulation of damaged proteins in cancer cells and ultimately triggering their death. The compound shows improved pharmacokinetic properties over earlier inhibitors, allowing for oral administration and more consistent drug exposure. It has been investigated in clinical trials both as a monotherapy and in combination with other anti-cancer agents such as immunomodulatory drugs and corticosteroids, enhancing treatment efficacy. Its targeted mechanism offers a strategic advantage in managing relapsed or refractory multiple myeloma cases.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | ฿1,100.00 |
+
-
|
| 10mg | 10-20 days | ฿1,034.00 |
+
-
|
| 50mg | 10-20 days | ฿3,250.00 |
+
-
|
| 250mg | 10-20 days | ฿7,100.50 |
+
-
|
MLN9708
MLN9708 is a proteasome inhibitor primarily used in the treatment of multiple myeloma, a type of blood cancer. It works by blocking the degradation of proteins involved in cell cycle regulation and apoptosis, leading to the accumulation of damaged proteins in cancer cells and ultimately triggering their death. The compound shows improved pharmacokinetic properties over earlier inhibitors, allowing for oral administration and more consistent drug exposure. It has been investigated in clinical trials both as a monotherapy and in combination with other anti-cancer agents such as immunomodulatory drugs and corticosteroids, enhancing treatment efficacy. Its targeted mechanism offers a strategic advantage in managing relapsed or refractory multiple myeloma cases.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :